Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.04−0.14 (-11.86%)
Close on Nov 16, 2026Market cap $104.35MP/E –Yield –
Cellectis r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $93.52M, up 3.3% from the year before. Over ten years it grew 4.9% a year on average. The highest annual figure on record is $117.84M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.52M | +3.3% |
| FY2024 | Dec 31, 2024 | $90.54M | +3.3% |
| FY2023 | Dec 31, 2023 | $87.65M | -10.1% |
| FY2022 | Dec 31, 2022 | $97.50M | -17.3% |
| FY2021 | Dec 31, 2021 | $117.84M | +52.9% |
| FY2020 | Dec 31, 2020 | $77.05M | -16.3% |
| FY2019 | Dec 31, 2019 | $92.04M | +20.2% |
| FY2018 | Dec 31, 2018 | $76.57M | -3.4% |
| FY2017 | Dec 31, 2017 | $79.23M | +1.0% |
| FY2016 | Dec 31, 2016 | $78.46M | +34.9% |
| FY2015 | Dec 31, 2015 | $58.15M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $24.98M | -2.6% |
| Q2 FY2025 | Jun 30, 2025 | $23.08M | -25.9% |
| Q2 FY2024 | Jun 30, 2024 | $23.52M | +2.9% |
| Q2 FY2023 | Jun 30, 2023 | $22.20M | -12.7% |
| Q2 FY2022 | Jun 30, 2022 | $25.63M | – |
| Q2 FY2021 | Jun 30, 2021 | $31.15M | – |
| Q2 FY2020 | Jun 30, 2020 | $22.86M | – |
| Q2 FY2019 | Jun 30, 2019 | $25.42M | – |
See a number that looks wrong?